During the past decade, a substantial increase in the use of second generation antipsychotics (SGAs) has occurredfor a number of juvenile psychiatric disorders, often as off-label prescriptions. Although they were thought to besafer than older, first generation antipsychotics, mainly due to a lower risk of neurological adverse reactions, recentstudies have raised significant concerns regarding their safety regarding metabolic, endocrinological and cardiovascularside effects. Aim of this paper is to update with a narrative review, the latest findings on safety of SGAs inyouths. Results suggest that different SGAs may present different safety profiles. Metabolic adverse events arethe most frequent and troublesome, with increasing evidences of heightened risk for type II diabetes mellitus.Results are discussed with specific emphasis on possible strategies of an active monitoring, which could enable bothpaediatricians and child psychiatrists to a possible prevention, early detection, and a timely management of such effects.
|Titolo:||Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists|
CATONE, GENNARO (Corresponding)
|Data di pubblicazione:||2016|
|Appare nelle tipologie:||1.1 Articolo in rivista|